JP2022502405A5 - - Google Patents
Info
- Publication number
- JP2022502405A5 JP2022502405A5 JP2021516916A JP2021516916A JP2022502405A5 JP 2022502405 A5 JP2022502405 A5 JP 2022502405A5 JP 2021516916 A JP2021516916 A JP 2021516916A JP 2021516916 A JP2021516916 A JP 2021516916A JP 2022502405 A5 JP2022502405 A5 JP 2022502405A5
- Authority
- JP
- Japan
- Prior art keywords
- solid form
- peaks
- solid
- form according
- xrpd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024104074A JP2024114885A (ja) | 2018-09-26 | 2024-06-27 | 多形化合物およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862736979P | 2018-09-26 | 2018-09-26 | |
| US62/736,979 | 2018-09-26 | ||
| PCT/US2019/053076 WO2020069068A1 (en) | 2018-09-26 | 2019-09-26 | Polymorphic compounds and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024104074A Division JP2024114885A (ja) | 2018-09-26 | 2024-06-27 | 多形化合物およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022502405A JP2022502405A (ja) | 2022-01-11 |
| JP2022502405A5 true JP2022502405A5 (enExample) | 2022-10-04 |
Family
ID=69885558
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021516916A Pending JP2022502405A (ja) | 2018-09-26 | 2019-09-26 | 多形化合物およびその使用 |
| JP2024104074A Pending JP2024114885A (ja) | 2018-09-26 | 2024-06-27 | 多形化合物およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024104074A Pending JP2024114885A (ja) | 2018-09-26 | 2024-06-27 | 多形化合物およびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10765693B2 (enExample) |
| EP (1) | EP3856741A4 (enExample) |
| JP (2) | JP2022502405A (enExample) |
| KR (1) | KR20210093864A (enExample) |
| CN (1) | CN112930349A (enExample) |
| AU (1) | AU2019346585B2 (enExample) |
| BR (1) | BR112021005290A2 (enExample) |
| CA (1) | CA3113250A1 (enExample) |
| EA (1) | EA202190576A1 (enExample) |
| IL (1) | IL281718A (enExample) |
| MX (1) | MX2021003515A (enExample) |
| WO (1) | WO2020069068A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3445368B1 (en) | 2016-04-21 | 2024-07-17 | Astrocyte Pharmaceuticals, Inc. | Compounds and methods for treating neurological and cardiovascular conditions |
| CN112218638A (zh) | 2018-02-09 | 2021-01-12 | 阿斯特罗赛特制药公司 | 用于治疗成瘾和相关病症的化合物和方法 |
| CN119264211A (zh) | 2018-08-27 | 2025-01-07 | 瑞泽恩制药公司 | 拉曼光谱在下游纯化中的应用 |
| IL310045A (en) | 2021-07-12 | 2024-03-01 | Acadia Pharm Inc | Crystalline forms of tropintide |
| KR20240122782A (ko) * | 2021-11-22 | 2024-08-13 | 아스트로사이트 파마슈티컬스, 인코포레이티드 | 신경학적 및 심혈관 상태를 치료하는 방법 |
| WO2024097387A1 (en) * | 2022-11-03 | 2024-05-10 | Astrocyte Pharmaceuticals, Inc. | Compositions for intravenous administration |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995002604A1 (en) | 1993-07-13 | 1995-01-26 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor agonists |
| US7348315B2 (en) | 1995-03-23 | 2008-03-25 | The University Of Connecticut | Methods of treating heart failure with modified ATP, ADP and AMP compounds |
| IL133680A0 (en) | 1999-09-10 | 2001-04-30 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
| US6586413B2 (en) | 1999-11-05 | 2003-07-01 | The United States Of America As Represented By The Department Of Health And Human Services | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
| EP1248869A2 (en) * | 2000-01-07 | 2002-10-16 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
| US7087589B2 (en) * | 2000-01-14 | 2006-08-08 | The United States Of America As Represented By The Department Of Health And Human Services | Methanocarba cycloakyl nucleoside analogues |
| US7589075B2 (en) | 2001-01-16 | 2009-09-15 | Can-Fite Biopharma Ltd. | Use of an adenosine A3 receptor agonist for inhibition of viral replication |
| US7414036B2 (en) | 2002-01-25 | 2008-08-19 | Muscagen Limited | Compounds useful as A3 adenosine receptor agonists |
| EP2410332A1 (en) | 2002-11-21 | 2012-01-25 | The University Of Utah | Method for identifying purinergic modulators of the olfactory system |
| GB0405009D0 (en) * | 2004-03-05 | 2004-04-07 | Cambridge Biotechnology Ltd | Analgesics |
| JP2008512457A (ja) | 2004-09-09 | 2008-04-24 | アメリカ合衆国 | Ａ３及びａ１アデノシン受容体作用薬としてのプリン誘導体 |
| WO2006091905A1 (en) * | 2005-02-25 | 2006-08-31 | Gilead Sciences, Inc. | Bicyclo (3.1.0) hexane derivatives as antiviral compounds |
| WO2007020018A1 (en) | 2005-08-12 | 2007-02-22 | Universite Libre De Bruxelles | Use of purinergic and pyrimidinergic receptor agonists for dendritic cells based immunotherapies |
| EP2049127B1 (en) | 2006-05-23 | 2014-11-26 | University of Connecticut | N-methanocarba derivatives to treat cardiac diseases |
| WO2008021552A2 (en) | 2006-08-18 | 2008-02-21 | Duke University | Biased ligands and methods of identifying same |
| US7867983B2 (en) | 2007-03-29 | 2011-01-11 | The University Of Connecticut | Methods to protect skeletal muscle against injury |
| JP5592262B2 (ja) | 2007-10-15 | 2014-09-17 | キャン−ファイト・バイオファーマ・リミテッド | 肝細胞の増殖を誘導する方法及びその使用 |
| CN101925610A (zh) | 2007-11-23 | 2010-12-22 | 巴尔-伊兰大学 | 不可水解的二磷酸核苷或三磷酸核苷衍生物及其用途 |
| US8916570B2 (en) | 2008-03-31 | 2014-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor agonists and antagonists |
| AU2009231978C1 (en) | 2008-03-31 | 2014-01-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Purine derivatives as A3 adenosine receptor- selective agonists |
| EP2278999B1 (en) | 2008-04-21 | 2025-01-29 | Dompé farmaceutici S.p.A. | Auris formulations for treating otic diseases and conditions |
| US8399018B2 (en) | 2008-07-21 | 2013-03-19 | Otonomy, Inc. | Controlled release ion channel modulator compositions and methods for the treatment of otic disorders |
| EP2331542B1 (en) | 2008-08-01 | 2016-07-27 | The United States of America, as Represented by The Secretary, Department of Health and Human Services | A3 adenosine receptor antagonists and partial agonists |
| US9181253B2 (en) | 2008-08-01 | 2015-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adenosine receptor agonists, partial agonists, and antagonists |
| US8685372B2 (en) | 2009-04-15 | 2014-04-01 | The Regents Of The University Of California | Peptides and aptamers for targeting of neuron or nerves |
| US8518957B2 (en) | 2009-12-02 | 2013-08-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methanocarba adenosine derivatives, pharmaceutical compositions, and method of reducing intraocular pressure |
| WO2011077435A1 (en) | 2009-12-22 | 2011-06-30 | Bar-Ilan University | Compositions and methods for reducing intraocular pressure |
| US8822434B2 (en) | 2010-02-22 | 2014-09-02 | The University Of Connecticut | Compositions and methods to treat cardiac diseases |
| US8691775B2 (en) | 2010-04-19 | 2014-04-08 | Back Bay Scientific, Llc | Use of drugs that activate P2Y receptors to enhance synaptogenesis |
| US9132131B2 (en) | 2011-04-21 | 2015-09-15 | Saint Louis University | Use of adenosine A3 receptor agonists for treatment of neuropathic pain |
| US20140241990A1 (en) | 2011-09-30 | 2014-08-28 | Tufts University | Methods of using adenosine a1 receptor activation for treating depression |
| SI2968385T1 (sl) | 2013-03-13 | 2018-10-30 | Tufts University | Uridin nukleozid derivati, sestavki in metode uporabe |
| US9963450B2 (en) | 2013-11-27 | 2018-05-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor agonists |
| HK1247119A1 (zh) | 2015-02-04 | 2018-09-21 | 贝克心脏与糖尿病研究所 | 一种治疗方法和用於所述治疗方法中的化合物 |
| EP3445368B1 (en) | 2016-04-21 | 2024-07-17 | Astrocyte Pharmaceuticals, Inc. | Compounds and methods for treating neurological and cardiovascular conditions |
| CN112218638A (zh) | 2018-02-09 | 2021-01-12 | 阿斯特罗赛特制药公司 | 用于治疗成瘾和相关病症的化合物和方法 |
-
2019
- 2019-09-26 EP EP19867559.7A patent/EP3856741A4/en active Pending
- 2019-09-26 KR KR1020217012486A patent/KR20210093864A/ko not_active Ceased
- 2019-09-26 EA EA202190576A patent/EA202190576A1/ru unknown
- 2019-09-26 CN CN201980071019.6A patent/CN112930349A/zh active Pending
- 2019-09-26 WO PCT/US2019/053076 patent/WO2020069068A1/en not_active Ceased
- 2019-09-26 MX MX2021003515A patent/MX2021003515A/es unknown
- 2019-09-26 BR BR112021005290-9A patent/BR112021005290A2/pt unknown
- 2019-09-26 CA CA3113250A patent/CA3113250A1/en active Pending
- 2019-09-26 JP JP2021516916A patent/JP2022502405A/ja active Pending
- 2019-09-26 US US16/583,570 patent/US10765693B2/en active Active
- 2019-09-26 AU AU2019346585A patent/AU2019346585B2/en active Active
-
2020
- 2020-07-28 US US16/940,451 patent/US11324769B2/en active Active
-
2021
- 2021-03-22 IL IL281718A patent/IL281718A/en unknown
-
2024
- 2024-06-27 JP JP2024104074A patent/JP2024114885A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022502405A5 (enExample) | ||
| JP2022088642A5 (enExample) | ||
| Walker | Prion-like mechanisms in Alzheimer disease | |
| JP2009509921A5 (enExample) | ||
| Wallace et al. | Drug targets for cognitive enhancement in neuropsychiatric disorders | |
| AU2016299486B2 (en) | 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| ES2617881T5 (es) | Dihidrato de compuesto de benzotiofeno y proceso de producción del mismo | |
| CA2560047A1 (en) | Substituted imidazoles and their use as opioid receptor modulators | |
| JP2022518632A5 (enExample) | ||
| JP6215971B2 (ja) | てんかん又はてんかん−関連症侯群の予防又は治療用フェニルアルキルカルバメート化合物｛ｐｈｅｎｙｌａｌｋｙｌｃａｒｂａｍａｔｅｃｏｍｐｏｕｎｄｓｆｏｒｕｓｅｉｎｐｒｅｖｅｎｔｉｎｇｏｒｔｒｅａｔｉｎｇｅｐｉｌｅｐｓｙｏｒｅｐｉｌｅｐｓｙ−ｒｅｌａｔｅｄｓｙｎｄｒｏｍｅ｝ | |
| JP2013544277A5 (enExample) | ||
| ZA200601324B (en) | Benzimidazolone compounds having 5-HT4 receptor agonistic activity | |
| JP2019525939A5 (enExample) | ||
| JP2023528450A5 (enExample) | ||
| ME01903B (me) | Hetrociklički sulfonamidi, njihova upotreba i farmaceutski pripravci | |
| TNSN07251A1 (en) | 2-phenyl-indoles as prostaglandin d2 receptor antagonists | |
| JP2010529081A5 (enExample) | ||
| RU2010123781A (ru) | Производные 4-(2-фенил)-морфолино)-2-оксопирролидин-1-ил)-n-(тиазол-2-ил)бензолсульфонамида и родственные соединения в качестве модуляторов ионных каналов для лечения боли | |
| KR102854594B1 (ko) | 신규한 화합물 | |
| JP2016506939A5 (enExample) | ||
| MX2019002444A (es) | Inhibidores de cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades. | |
| GEAP202516743A (en) | Phthalazine derivatives useful as inhibitors of nod-like receptor protein 3 | |
| CA2545092A1 (en) | Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity | |
| JP2022523702A5 (enExample) | ||
| GT200600457A (es) | Sal de fosfato dihidrogeno como antagonistas del receptor de prostaglandina d2 |